HELIX BIOPHARMA CORP. ANNOUNCES FISCAL 2023 YEAR-END RESULTS

Helix BioPharma Corp. (TSX: “HBP”), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the 2023 fiscal year ended July 31, 2023.